Bisoprolol-Teva, 10 mg 30 pcs

Pharmacotherapeutic group:

Beta1-adrenoblocker selective

ATX code: C07AB07

Pharmacological Properties

Pharmacodynamics

Indications

Active ingredient

Composition

1 tablet contains: the active ingredient: bisoprolol fumarate 5.00 or 10.00 mg; excipients: microcrystalline cellulose (21.10/20.00 mg), mannitol (148.50/144.60 mg), croscarmellose sodium (1.80/1.80 mg), magnesium stearate (3.60/3.60 mg); film coating: hypromellose 2.19 mg, titanium dioxide 0.88 mg, macrogol-6000 0.53 mg;

Prepackaged shell “OPADRY® 03F280038 white (60.83% hypromellose, 24.45% titanium dioxide, 14.72% macrogoal-6000).

How to take, the dosage

Interaction

Special Instructions

Synopsis

Contraindications

Side effects

The incidence of adverse reactions below was determined according to the following (World Health Organization classification): very common – at least 10%; common – at least 1%, but less than 10%; infrequent – at least 0.1%, but less than 1%; rare – at least 0.01%, but less than 0.1%; very rare – less than 0.01%, including individual reports.

Heart and vascular side: very often – reduced HR (bradycardia, especially in patients with CHF); sensation of palpitation, often – marked decrease in BP (especially in patients with CHF), manifestation of angiospasm (increased peripheral circulatory disorders, feeling of cold in the extremities (paresthesias); infrequent – AV conduction disorders (up to complete transverse blockade and cardiac arrest), arrhythmias, orthostatic hypotension, worsening of CHF with development of peripheral edema (edema of ankles, feet, dyspnea), chest pain.

Nervous system disorders:often – dizziness headache, asthenia, fatigue, sleep disorders, depression, anxiety; rarely – confusion or short-term memory loss, “nightmare” dreams, hallucinations, myasthenia, tremor, muscle cramps. Usually these phenomena are mild and usually go away within 1-2 weeks after the start of treatment.

Sensory organs: frequently – visual impairment, decreased tear production (should be considered when wearing contact lenses), tinnitus, decreased hearing, ear pain; very rarely – dry and painful eyes, conjunctivitis, taste disorders.

The respiratory system: infrequent – bronchospasm in patients with bronchial asthma or obstructive airway disease; rare – allergic rhinitis; nasal congestion.

Digestive system disorders: frequently – nausea, vomiting, diarrhea, constipation, dry oral mucosa, abdominal pain; rarely – hepatitis, increased activity of liver enzymes (alanine aminotransferase, aspartate aminotransferase), increased concentration of bilirubin, change in taste.

Musculoskeletal system disorders: infrequent – arthralgia, back pain.

System of the genitourinary system: very rarely – impaired potency, weakened libido.

Laboratory findings: frequently – increased concentration of triglycerides in the blood; in isolated cases – thrombocytopenia, agranulocytosis, leukopenia.

Allergic reactions: frequently – skin itching, rash, urticaria

Skin reactions:seldom – increased sweating, skin hyperemia, exanthema, psoriasis-like skin reactions; very rarely – alopecia, beta-adrenoblockers may aggravate the course of psoriasis.

Others:withdrawal syndrome (increased frequency of angina attacks, increased BP).

Overdose

Pregnancy use

Similarities